Comparing two types of nerve blocks for treating chronic migraines
Efficacy of Ultrasound Guided Block of Stellate Ganglion Versus Greater Occipital Nerve in Chronic Resistant Migraine Patients and Its Correlation to Calcitonin Gene Related Peptide (CGRP)
This study is testing which of two nerve block treatments works better for people with chronic migraines that haven't improved with other medications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06662461 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of ultrasound-guided Stellate Ganglion block versus Greater Occipital Nerve block in patients suffering from chronic resistant migraines. A total of 40 patients who have not responded to at least two anti-migraine medications will be randomly assigned to one of the two treatment groups. The study will also assess the correlation between the treatment effects and serum levels of Calcitonin Gene Related Peptide (CGRP). The goal is to determine which nerve block technique provides better relief for migraine sufferers.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with chronic resistant migraines who have not responded to or are intolerant to at least two anti-migraine medications.
Not a fit: Patients with space-occupying lesions, coagulation disorders, systemic or local infections, or drug allergies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new effective treatment option for patients with chronic resistant migraines.
How similar studies have performed: Other studies have shown promising results with similar nerve block techniques for migraine treatment, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals diagnosed with chronic resistant migraine after using or intolerability to 2 or more of anti-migraine drugs for at least 3 months Exclusion Criteria: * Patients with a space-occupying lesion. * Coagulation disorders. * Systemic or local infection and drug allergies.
Where this trial is running
Cairo
- Ain Shams University Hospital — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Mai Fathy Ass.Prof.Mai Fathy
- Email: maifathy@med.asu.edu.eg
- Phone: +2001023868846
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.